目的 分析宁夏回族自治区人民医院新型抗肿瘤药物的使用情况，为合理应用及规范化管理提供参考。方法 对2019—2022年宁夏回族自治区人民医院新型抗肿瘤药物的药品规格、年销售金额、用药频度（DDDs）、日均费用（DDC）以及排序比（B/A）进行统计分析。结果 2019—2022年，宁夏回族自治区人民医院新型抗肿瘤药物品规逐年增加。2022年销售金额激增，较2019年增长3.2倍。大多数药物DDDs逐年上升，21种药物DDC较2021年下降，吉非替尼、伊马替尼使用频率高，DDC低，B/A远大于1，显示出良好的同步性。结论 随着新医改政策的实施，宁夏回族自治区人民医院新型抗肿瘤药物品种增多、使用量逐渐增加，药物价格下降，新型抗肿瘤药的使用基本合理。

Objective To analyze the application situation of new antitumor drugs in the People’s Hospital of Ningxia Hui Autonomous Region, and to provide references for the rational use and standardized management. Methods The new antitumor drugs in People’s Hospital of Ningxia Hui Autonomous Region from 2019 to 2022 were analyzed statistically of the drug specifications, annual consumption sum, medication frequency (DDDs), average daily cost (DDC), and ranking ratio (B/A). Results From 2019 to 2022, the regulations of new antitumor drugs in People’s Hospital of Ningxia Hui Autonomous Region increased year by year. Consumption sum increased sharply in 2022, nearly 3.2 times compared with 2019. The DDDs of most drugs increased year by year, and the DDC of twenty-one drugs decreased compared with 2021. Gefitinib and imatinib were used with high frequency, low daily cost, and B/A was much higher than 1, shows good synchronization. Conclusion With the implementation of the new medical reform policies, the variety and use of new antitumor drugs in People’s Hospital of Ningxia Hui Autonomous Region have increased gradually, and the price has decreased. The utilization of new antitumor drugs is basically reasonable.

R978.7